Cardioprotective effects of luteolin during ischemia-reperfusion injury in rats

Circ J. 2011;75(2):443-50. doi: 10.1253/circj.cj-10-0381. Epub 2010 Dec 18.

Abstract

Background: Antioxidants effectively reduce ischemia-reperfusion (IR) injury. The cardioprotective effects of luteolin, a flavonoid that exhibits antioxidant properties and is widely available in many fruits and vegetables, were examined in rats subjected to myocardial IR injury.

Methods and results: Rats were subjected to myocardial ischemia or reperfusion injury to evaluate the antiarrhythmic effects of luteolin. Myocardial infarct size was determined histochemically with triphenyltetrazolium chloride staining of the left ventricle. Luteolin was administered intravenously 15min before occlusion of the coronary artery. The incidence and duration of ventricular tachycardia and ventricular fibrillation and mortality during myocardial ischemia were significantly reduced by luteolin (10µg/kg). Similarly, luteolin (1µg/kg) reduced ventricular arrhythmias and mortality during the reperfusion phase. Pretreatment with luteolin decreased plasma lactate dehydrogenase and nitric oxide (NO) levels. Luteolin (10µg/kg) significantly reduced the myocardial infarct size, as well as malondialdehyde production in tissue samples of myocardial IR injury. Luteolin also downregulated inducible NO synthase protein and mRNA expression, but did not significantly alter neuronal NO synthase or endothelial NO synthase expression.

Conclusions: Luteolin is capable of protecting the myocardium against IR injury. The actions of luteolin are at least partly mediated through downregulation of NO production and its own antioxidant properties.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Arrhythmia Agents / pharmacology
  • Anti-Arrhythmia Agents / therapeutic use*
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Cardiotonic Agents / pharmacology
  • Cardiotonic Agents / therapeutic use*
  • Drug Evaluation, Preclinical
  • Gene Expression Regulation, Enzymologic / drug effects
  • Hemodynamics / drug effects
  • Isoenzymes / biosynthesis
  • Isoenzymes / genetics
  • L-Lactate Dehydrogenase / blood
  • Luteolin / pharmacology
  • Luteolin / therapeutic use*
  • Male
  • Myocardial Infarction / blood
  • Myocardial Infarction / complications
  • Myocardial Infarction / pathology
  • Myocardial Reperfusion Injury / blood
  • Myocardial Reperfusion Injury / drug therapy*
  • Myocardium / enzymology
  • Nitric Oxide / blood
  • Nitric Oxide Synthase / biosynthesis
  • Nitric Oxide Synthase / genetics
  • RNA, Messenger / biosynthesis
  • RNA, Messenger / genetics
  • Rats
  • Rats, Sprague-Dawley
  • Tachycardia, Ventricular / etiology
  • Tachycardia, Ventricular / prevention & control
  • Ventricular Fibrillation / etiology
  • Ventricular Fibrillation / prevention & control

Substances

  • Anti-Arrhythmia Agents
  • Antioxidants
  • Cardiotonic Agents
  • Isoenzymes
  • RNA, Messenger
  • Nitric Oxide
  • L-Lactate Dehydrogenase
  • Nitric Oxide Synthase
  • Luteolin